Equillium Inc. Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 94.02. In total, the insiders bought 4 291 529 and sold 192 250 EQ shares in the last 100 trades.

Insider Power

(Last 100 transactions)
94.02
Buy 4 291 529 Shares
Sell 192 250 Shares

Historical Insider Trades

Date Type Action Person Amount
May 22, 2024 Stock Option (right to buy) Buy Demski Martha J 20 000
May 22, 2024 Stock Option (right to buy) Buy Pruzanski Mark 20 000
May 22, 2024 Stock Option (right to buy) Buy Manian Bala S 20 000
May 22, 2024 Stock Option (right to buy) Buy Mcdermott Charles Douglas 20 000
May 22, 2024 Stock Option (right to buy) Buy Xu Yu (katherine) 20 000
May 22, 2024 Stock Option (right to buy) Buy Troupin Barbara 20 000
Mar 06, 2024 Common Stock Buy Tom Penny 0
Mar 06, 2024 Employee Stock Option (right to buy) Buy Tom Penny 45 000
Mar 06, 2024 Employee Stock Option (right to buy) Buy Tom Penny 40 000
Mar 06, 2024 Employee Stock Option (right to buy) Buy Tom Penny 60 000
Mar 06, 2024 Employee Stock Option (right to buy) Buy Tom Penny 40 000
Mar 06, 2024 Employee Stock Option (right to buy) Buy Tom Penny 100 000
Mar 06, 2024 Employee Stock Option (right to buy) Buy Tom Penny 100 000
Jan 02, 2024 Employee Stock Option (right to buy) Buy Bradbury Daniel 50 000
Jan 02, 2024 Employee Stock Option (right to buy) Buy Steel Bruce D. 410 000
Jan 02, 2024 Employee Stock Option (right to buy) Buy Connelly Stephen 175 000
Jan 02, 2024 Employee Stock Option (right to buy) Buy Rothman Joel 175 000
Jan 02, 2024 Employee Stock Option (right to buy) Buy Zedelmayer Christine 175 000
Jan 02, 2024 Employee Stock Option (right to buy) Buy Keyes Jason A 175 000
Dec 08, 2023 Common Stock Buy Rothman Joel 8 804
Dec 08, 2023 Common Stock Buy Zedelmayer Christine 8 804
Dec 08, 2023 Common Stock Buy Keyes Jason A 8 805
Jun 09, 2023 Common Stock Buy Rothman Joel 15 000
Jun 09, 2023 Common Stock Buy Zedelmayer Christine 15 000
Jun 09, 2023 Common Stock Buy Keyes Jason A 15 000
Click to get the best stock tips daily for free!

About Equillium Inc.

Equillium. Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib... EQ Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT